Phase 1 single ascending dose study of ARGX-113 in healthy volunteers

Trial Profile

Phase 1 single ascending dose study of ARGX-113 in healthy volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs ARGX 113 (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 25 Aug 2016 According to an arGEN-X media release, complete data set from the study will be presented at argenx R&D day, 22 September 2016.
    • 09 Jan 2016 New trial record
    • 05 Jan 2016 According to an arGEN-X media release, the dose-escalation part of this study has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top